President and CEO, Rowe Neurology Institute, Lenexa, KS,
President and CEO Neurrow Pharamceuticals, Inc
Adjunct Professor of Neurology, University of Kansas School of Medicine
My time at Duke, Hopkins, and the NIH helped hone a vision for what a physician scientist can be. After completion of my Neurology residency at Hopkins in 1977 I joined the faculty of the University of Kansas School of Medicine, combining clinical practice with a basic research program using primary cultures of pineal cells and sympathetic neurons. After rising through the academic ranks, I founded the independent Rowe Neurology Institute, in Lenexa, KS.
The Rowe Neurology Institute has three arms: what is now a clinical concierge neurology practice; a non-profit research foundation which does basic and clinical research (I have been the PI on over 150 clinical trials over the past 25 years); and a pharmaceutical and device development incubator. The clinical practice is a tertiary referral center specializing in Multiple Sclerosis, Headache, Sleep Medicine, and Hypermobility Syndrome, the latter arising from our observed links among migraine, sleep disorders and joint hypermobility.
With my wife Elizabeth Rowe, Ph.D., MBA, I founded Verrow Pharmaceuticals, Inc, which recently sold to Ligand Pharmaceuticals, Inc, and its first product, a kidney safe iodinated contrast agent, has now completed Phase I clinical trials. Neurrow Pharmaceuticals, Inc. the most recent product of our incubator, is focused on neurodegenerative disease. Betsy and I have two sons and five grandchildren and our hobbies include flying, sailing, bluegrass music, cowboy mounted shooting, and writing. Board Certifications include Neurology, Sleep Medicine, Electrodiagnostic Medicine, Neuroimaging, and EEG.
See Dr. Rowe’s presentation at Kansas University Medical School Neurology Grand Rounds Why Medicine Needs Physician Scientists and How to Train Them
Selected Publications
1. Rowe, V.D., and Parr, J.: Developmental Changes in the Stimulation of Serotonin N-Acetyltransferase Activity and Melatonin Synthesis in the Rat Pineal in Monolayer Culture, Journal Pharmacol Exp Ther 218:(1):97-102, 1981.
2. Rowe, V.D. Sea Creatures and Other Poems, Whirlybird Press, 1995.
3. Rowe, V., Use of Regularly Scheduled High Dose Intravenous Methotrexate
Therapy, with Interim Administration of Immunomodulatory Agents, to Treat Multiple Sclerosis and Other Diseases of the Central Nervous System. (US Patent 6,903,100 B2; 2005)
4. Rowe, V., Compositions Useful for Reducing Nephrotoxicity and Methods of Use Thereof. (US Patent No.: 7,658,913 B2, 2010) (also granted in Europe and other countries)
5. Rowe, V., Compositions Useful for Reducing Toxicity Associated with Gadolinium-based Contrast Agents. (Patent No.: US 20090155181 A1)
6. Rowe, V.D .The Ride, Whirlybird Press, 2011.
7. Rowe, E.S., Rowe, V.D., Biswas, S., Mosher, G., Insisienmay, L., Ozias, M.K., Gralinski, M.R., Hunter, J.H., Barnett, J.S.: Preclinical Studies of a Kidney Safe Iodinated Contrast Agent. Journal of Neuroimaging, 26:511-518, September 2016.
8. Beh, SC, Kildebeck, E, Narayan, R., Desena, A., Schell, D., Rowe, ES., Rowe, V., Burns, D., Whitworth, L, Frohman, TC., Greenberg, B., Frohman, EM. Treatment of Severe CNS Inflammatory Syndromes With High-Dose IV Methotrexate with Leucovorin Rescue. Journal of Neurological Sciences 372, 187-195, 2017.
9. Frohman, EM.,Villemarette-Pittman, N., Cruz, RA., Longmuir, R., Rowe, V., Rowe, ES., Varkey, TC., Stienman, L, Zamil, S., Frohman, TC. Part II. High-Dose Methotrexate with Leucovorin Rescue for Severe COVID-19: An Immune Stabilization Strategy for SARS-CoV-2 Induced ‘PANIC’* Attack. In Press Journal of Neurological Sciences, May 2020.